Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 63.32
-2.63 (-3.99%)
At close: Jan 27, 2026
28.80% (1Y)
| Assets | 42.26M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +28.80% |
| Volume | 3,307 |
| Open | 64.60 |
| Previous Close | 65.95 |
| Day's Range | 62.85 - 64.60 |
| 52-Week Low | 38.76 |
| 52-Week High | 65.95 |
| Beta | 0.35 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 28.80% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.99%.
Top Holdings
14.95% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna, Inc. | MRNA | 2.07% |
| Revolution Medicines, Inc. | RVMD | 1.77% |
| Vaxcyte, Inc. | PCVX | 1.44% |
| GRAIL, Inc. | GRAL | 1.42% |
| Amicus Therapeutics, Inc. | FOLD | 1.40% |
| Krystal Biotech, Inc. | KRYS | 1.40% |
| Mirum Pharmaceuticals, Inc. | MIRM | 1.40% |
| Alkermes plc | ALKS | 1.38% |
| Praxis Precision Medicines, Inc. | PRAX | 1.35% |
| Halozyme Therapeutics, Inc. | HALO | 1.32% |